XM does not provide services to residents of the United States of America.

China, Hong Kong stocks rebound in choppy trade on caution amid steady lending rates



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>China, Hong Kong stocks rebound in choppy trade on caution amid steady lending rates</title></head><body>

Updates closing price, adds movers

HONG KONG, Nov 20 (Reuters) -China and Hong Kong stocks edged higher in volatile trading on Wednesday, with mainland shares supported by AI stocks ahead of Nvidia's earnings later in the day, while investorsremained cautious amid steady lending rates.

** The Shanghai Composite index .SSEC closed up0.66% at 3,367.99.

** The blue-chip CSI300 index .CSI300 ended up0.22%, with the consumerstaples sector .CSI000912 and the healthcare sub-index .CSI300HC closing 0.37% and 2.13% higher, respectively.

** The CSI300 Artificial Intelligence Index .CSI930713 climbed 1.5% ahead of Nvidia's.NVDA.O report card later in the day.

** Hong Kong's benchmark Hang Seng Index .HSI gained 0.21% at 19,702.79.

** China's central bank left key lendingrates unchanged at the monthly fixing on Wednesday, after recent rate cuts squeezed banks' profitability and the yuan came underfresh pressure with Donald Trump's imminent return to the White House.

** Market fundamentals have improved following the recent policy measures buthaven't shown significant strength yet. The market rotation among major sectors is likely to stay with no clear signs of earnings bottoming out, analysts at Sinolink Securities said in a note.

** Around the region, MSCI's Asia ex-Japan stock index .MIAPJ0000PUS was weaker by 0.19%.

** Chinese ADRs .HXC fell 0.75% overnight.

** Elsewhere, major Chinese fund companies announced a reduction in fees for a batch of equity exchange-traded funds (ETFs), after China's chief securities regulator Wu Qing pledged to encourage index investment and fund industry fee reform.



Reporting by Hong Kong Newsroom; Editing by Rashmi Aich and Sumana Nandy

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.